



PATENT Customer No. 22,852 Attorney Docket No. 09095.0009-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Wang et al.) Group Art Unit: 1614
Application No.: 10/773,332) Examiner: Not Yet Assigned
Filed: February 9, 2004)
For: ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATIVES AND THEIR USE AS CELL ADHESION INHIBITING ANTI- INFLAMMATORY AND IMMUNE- SUPPRESSIVE AGENTS) Confirmation No.: 8910

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were previously submitted in a prior application, application no. 09/888,840, filed June 25, 2001, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants note that an error was made in the citation of Wegner et al., "Intercellular Adhesion Molecule-1 Contributes to Pulmonary

Oxygen Toxicity in Mice: Role of Leukocytes Revised", *Lung*, 170:267-279 (1992) in the '840 application. This Wegner article was cited in the parent '840 application as being in *J. Immunol.*, 154:1350-1363 (1995), which is the correct citation of the Mulligan reference, Mulligan et al., "Compartmentalized Roles for Leukocytic Adhesion Molecules in Lung Inflammatory Injury", *J. Immunol.*, 154:1350-1363 (1995). The present Form 1449 gives the correct citation of both the Wegner and Mulligan references. Copies of these two references are enclosed for consideration by the Examiner.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

PATENT Customer No. 22,852 Attorney Docket No. 09095.0009-01000

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: __June 29, 2004

Maria T. Bautista

Reg. No. 52,516



EASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In re Application of: Wang et al.

Application No.: 10/773,332

Group Art Unit: 1614

Filed: February 9, 2004

Examiner: Not Yet Assigned

For:

ARYL PHENYLHETEROCYCLYL SULFIDE DERIVATIVES AND THEIR USE AS

CELL ADHESION-INHIBITING ANTI-INFLAMMATORY AND IMMUNE-

SUPPRESSIVE AGENTS

Information Disclosure Statement (3 pages) 1.

PTO 1449 Form (7 pages) 2.

Reference(s) Enclosed (2) 3.

Dated June 29, 2004

Docket No.: 09095,0009-01000

MTB/GXP/J.Leveille - CAMBRIDGE

Due Date: None



Atty. Docket No.	7.09005.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.		
Filing Date	February 9, 2004	Group:	1614

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	3,948,893	04/06/1976	Aichinger et al.	260	248	03/18/1974
	4,973,599	11/27/1990	Gilman et al.	514	398	03/14/1989
	5,028,629	07/02/1991	Hite et al.	514	575	03/28/1990
	5,208,253	05/04/1993	Boschelli et al.	514	443	02/24/1992
	5,776,951	07/07/1998	Arrowsmith et al.	514	328	04/11/1996
	5,817,862	10/06/1998	Poetsch et al.	560	104	08/22/1996
	5,883,106	03/16/1999	Stevens et al.	514	277	02/06/1998
	5,883,133	03/16/1999	Schwark et al.	514	619	07/24/1996
	5,912,266	06/15/1999	Perez	514	460	08/13/1997
	6,110,922	08/29/2000	Link et al.	514	259	12/29/1998
	6,211,215 B1	04/03/2001	Momose et al.	514	374	11/18/1998
	S/N 09/285,325		Fowler, et al.			04/02/1999
	S/N 09/285,477		Staunton, et al.			04/02/1999
	S/N 09/541,795		Link et al.			03/31/2000
	S/N 09/606,717		Wang et al.			06/29/2000
	S/N 09/695,040		Gunawardana	J = 1		10/24/2000

FOREIGN PATENT DOCUMENTS						
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
AT 392 788 B	06/10/1991	Austria	C07D	401/12	No	
DE 2 123 383	02/12/1971	Germany	C07B	29/00	No	
EP 0 219 756 A1	04/29/1987	Europe	C07D	295/18	No	
 EP 0 262 845 A1	04/06/1988	Europe	C07D	401/12		
EP 0 455 356 A1	11/06/1991	Europe	A61K	31/41		
EP 0 710 654 A1	05/08/1996	Europe	C07D	249/14		
EP 0 835 867 A1	04/15/1998	Europe	C07D	295/08		
EP 0 887 340 A1	12/30/1998	Europe	C07C	235/34		

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.		
Filing Date	February 9, 2004	Group:	1614

	FOREIGN PATENT DOCUMENTS					
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	EP 1 052 238 A1	11/15/2000	Europe	C07C	43/215	
	GB 2 117 760 A	10/19/1983	United Kingdom	C07D	213/62	
	JP 2000-72766	03/07/2000	Japan	C07D	311/58	No
*	WO 96/26921	09/06/1996	PCT	C07C	317/44	No
	WO 98/13347	04/02/1998	PCT	C07D	213/53	
	WO 98/39303	09/11/1998	PCT	C07D	233/76	
	WO 99/11258	03/11/1999	PCT	A61K	31/365	
	WO 99/20617	04/29/1999	PCT	C07D	285/12	
	WO 99/20618	04/29/1999	PCT	C07D	285/135	
	WO 99/49856	10/07/1999	PCT	A61K	31/00	
	WO 00/15604	03/23/2000	PCT	C07C	235/20	No
	WO 00/15645	03/23/2000	PCT	C07F	9/572	No
	WO 00/21920	04/20/2000	PCT	C07C	235/52	
	WO 00/39081	07/06/2000	PCT	C07C	323/00	
	WO 00/48989	08/24/2000	PCT	C07C	235/26	
	WO 00/59880	10/12/2000	PCT	C07C	323/62	
	WO 00/59878	10/12/2000	PCT	C07C	323/37	
	WO 00/60355	10/12/2000	PCT	G01N	33/53	
	WO 01/06984 A2	02/01/2001	PCT	A61K		
	WO 01/07052 A1	02/01/2001	PCT	A61K	31/55	
	WO 01/27102 A1	04/19/2001	PCT	C07D	401/06	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Ali et al., "Mechanisms of Inflammation and Leukocyte Activation", Med. Clin. North America, 28 (1997)				
	Aoudjit et al., "Protection from Lymphoma Cell Metastasis in ICAM-1 Mutant Mice: A Posthoming Event", J. Immunol., 161:2333-2338 (1998)			

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.		
Filing Date	February 9, 2004	Group:	1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Bella et al., "The Structure of the Two Amino-Termiinal Domains of Human ICAM-1 Suggests How It Functions as a Rhinovirus Receptor and as an LFA-1 Integrin Ligand", <i>PNAS.</i> , 95:4140-4145 (1998)
	Bennett et al., "An ICAM-1 Antisense Oligonucleotide Prevents and Reverses Dextran Sulfate Sodium-Induced Colitis in Mice", <i>J. Pharmacology Exper. Therapeutics</i> , 280:988-1000 (1997)
·	Berge et al., "Pharmaceutical Salts", J. Pharmaceutical Sciences, 66:1-19 (1977)
	Binnerts et al., "How LFA-1 Binds to Different Ligands", Immunol. Today, 20:240-245 (1999)
	Bloemen et al., "LFA-1, and Not Mac-1, is Crucial for the Development of Hyperreactivity in a Murine Model of Nonallergic Asthma", <i>Am. J. Respir. Crit. Med.</i> , 153:521-529 (1996)
	Boschelli et al., "Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent", <i>J. Med. Chem.</i> , 38:4597-4614 (1995)
	Bowes et al., "Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Medical", <i>Experimental Neurology</i> , 119:215-219 (1993)
	Carlos et al., "Leukocyte-Endothelial Adhesion Molecules", <i>Blood</i> , 84:2068-2101 (1994)
	Chopp et al., "Postischemic Administration of an Anti-Mac-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats", <i>Stroke</i> , 25:869-876 (1994)
	Clark et al., "Reduction of Central Nervous System Ischemic Injury by Monoclonal Antibody to Intercellular Adhesion Molecule", <i>J. Neurosurg.</i> , 75;623-627 (1991)
	Cosimi et al., "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) In Nonhuman Primates with Renal Allografts", <i>J. Immunol.</i> , 144:4604-4612 (1990)
	DeMeester et al., "Attenuation of Rat Lung Isograft Reperfusion Injury with a Combination of Anti-ICAM-1 and Anti- β_2 Integrin Monoclonal Antibodies", <i>Transplantation</i> , 62:1477-1485 (1996)
	Edwards et al., "Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-Associated Antigén-1", <i>J. Biol. Chem.</i> , 273:28937-28944 (1998)
	Emeigh et al., "Small-Molecule Antagonists of LFA-1 Mediated Cell Adhesion", 221st ACS Nat'l Mtg, San Diego, CA, USA:MEDI 256 (2001)
	Fisher et al., "Identification of the Binding Site in Intercellular Adhesion Molecule 1 for Its Receptor, Leukocyte Function-Associated Antigen 1", <i>Mol. Biol. Cell</i> , 8:501-515 (1997)
	Gadek et al., "Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein-Protein Interaction Novel Immunomodulatory Agents", 220th ACS Nat'l Mtg, Washington, DC, USA: MEDI 177 (2000)
	Gahmberg, C., "Leukocyte Adhesion:CD11/CD18 Integrins and Intercellular Adhesion Molecules", Curr. Opin. Cell. Biol., 9:643-650 (1997)
	Gahmberg, C.G., "Leukocyte Adhesion: Structure and Function of Human Leukocyte $\[mathbb{R}_2$ -Integrins and Their Cellular Ligands", <i>Eur. J. Biochem.</i> , 245:215-232 (1997)

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332	
Applicant	WANG et al.			
Filing Date	February 9, 2004	Group:	1614	

•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Green et al., "T Cell Receptor Stimulation, but Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events", <i>Eur. J. Immunol.</i> , 24:265-272 (1994)
	Gorczynski et al., "A Role for Nonspecific (Cyclosporin A) or Specific (Monoclonal Antibodies to ICAM-1, LFA-1, and IL-10) Immunomodulation in the Prolongation of Skin Allografts After Antigen-Specific Pretransplant Immunization or Transfusion ¹ ", <i>J. Immunol.</i> , 152:2011-2019 (1994)
	Gross et al., "Identification of LFA-1 as a Candidate Autoantigen in Treatment-Resistant Lyme Arthritis", Science, 281:703-706 (1998)
	Gute et al., "Inflammatory Responses to Ischemia and Reperfusion in Skeletal Muscle", <i>Mol. Cell. Biochem.</i> , 179:169-187 (1998)
	Hallahan et al., "Intercellular Adhesion Molecule 1 Knockout Abrogates Radiation Induced Pulmonary Inflammation", <i>PNAS</i> , 94:6432-6437 (1997)
	Halloran et al., "Cellular Adhesion Molecules in Rat Adjuvant Arthritis", Arthritis & Rheumatism, 39:810-819 (1996)
	Hamilton et al., "Fluorenylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes", <i>J. Med. Chem.</i> , 38:1650-1656 (1995)
	Harning et al., "Reduction in the Severity of Graft-Versus-Host Disease and Increased Survival in Allogeneic Mice by Treatment with Monoclonal Antibodies to Cell Adhesion Antigens LFA-1α and MALA-2", <i>Transplantation</i> , 52:842-845 (1991)
	Hartman et al., "Protection of Ischemic/Reperfused Canine Myocardium by CL18/6, a Monoclonal Antibody to Adhesion Molecule ICAM-1", Cardiovascular Res., 30:47-54 (1995)
	Hasegawa et al., "Prevention of Autoimmune Insulin-Dependent Diabetes in Non-Obese Diabetic Mice by Anti-LFA-1 and Anti-ICAM-1 mAb", Int'l Immunology, 6:831-838 (1994)
	He et al., "Effect of LFA-1 and ICAM-1 Antibody Treatment on Murine Corneal Allograft Survival", Invest. Ophthalmol. Vis. Sci., 35:3218-3225 (1994)
	Henricks et al., "Pharmacological Modulation of Cell Adhesion Molecules", Eur. J. Pharmacol., 344:1-13 (1998
	Herold et al., "Prevention of Autoimmune Diabetes by Treatment with Anti-LFA-1 and Anti-ICAM-1 Monoclonal Antibodies", Cell. Immunol., 157:489-500 (1994)
	Higuchi et al., <i>Pro-drugs as Novel Drug Delivery Systems</i> , <i>ACS Symposium Series 14</i> (1975) (face pages and table of contents only)
	Horgan et al., "Role of ICAM-1 in Neutrophil-Mediated Lung Vascular Injury After Occlusion and Reperfusion", Am. J. Physiol., 261:H1578-H1584 (1991)
	Huang et al., "A Binding Interface on the I Domain of Lymphocyte Function-Associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1)", <i>J. Biol. Chem.</i> , 270:19008-19016 (1995)
	Huth et al., "NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding", PNAS, 97:5231-5326 (2000)

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.		
Filing Date	February 9, 2004	Group:	1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Isobe et al., "Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1", Science, 255:1125-1127 (1992)
	Kakimoto et al., "The Effect of Anti-Adhesion Molecule Antibody on the Development of Collagen-Induced Arthritis", Cell. Immunol., 142:326-337 (1992)
	Kallen et al., "Structural Basis for LFA-1 Inhibition Upon Lovastatin Binding to the CD11a I-Domain", J. Mol. Biol., 292:1-9 (1999)
	Kawasaki et al., "Antibodies Against Intercellular Adhesion Molecule-1 and Lymphocyte Function-Associated Antigen-1 Prevent Glomerular Injury in Rat Experimental Crescentic Glomerulonephritis", <i>J. Immunol.</i> , 150:1074-1083 (1993)
	Kelly et al., "Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion", J. Immunol., 163:5173-5177 (1999)
	Kishimoto et al., "Integrins, ICAMs and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites", <i>Advances Pharmacol.</i> , 25:117-169 (1994)
-	Knoerzer et al., "Clinical and Histological Assessment of Collagen-Induced Arthritis Progression in the Diabetes-Resistant BB/Wor Rat", <i>Toxicologic Pathol.</i> , 25:13-19 (1997)
	Landis et al., "Involvement of the "I" Domain of LFA-1 in Selective Binding to Ligands ICAM-1 and ICAM-3", J. Cell Biol., 126:529-537 (1994)
	Lawrence et al., "Leukocytes Roll on a Selectin at Physiologic Flow Rates: Distinction from and Prerequisite for Adhesion through Integrins", Cell, 65:859-873 (1991)
	Ley et al., "Lectin-Like Cell Adhesion Molecule 1 Mediates Leukocyte Rolling in Mesenteric Venules In Vivo", <i>Blood</i> , 77:2553-2555 (1991)
	Link et al., "Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonists", <i>Bioorganic Medicinal Chem. Letters</i> , 11:973-976 (2001)
	Liu, G., "Small Molecule Antagonists of the LFA-1/ICAM-1 Interaction as Potential Therapeutic Agents", Expert Opin. Ther. Patents, 11:1383-1393 (2001)
	Liu et al, "Novel — Arlythio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanisms of Inhibition and Structure-Based Improvement of Pharmaceutical Properties", <i>J. Med. Chem.</i> , 44:1202-1210 (2001)
	Liu et al., "Discovery of Novel p - Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction, 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead", <i>J. Med. Chem.</i> , 43:4025-4040 (2000)
	Lu et al., "An Isolated, Surface-Expressed I Domain of the Integrin αLβ2 is Sufficient for Strong Adhesive Function when Locked in the Open Conformation with a Disulfide Bond", PNAS, 98:2387-2392 (2001)
	March J., Advanced Organic Chem., pp. 16-18 (1985)
	Mulligan et al., "Compartmentalized Roles for Leukocytic Adhesion Molecules in Lung Inflammatory Injury", <i>J. Immunol.</i> , 154:1350-1363 (1995)

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.	•	
Filing Date	February 9, 2004	Group:	1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Nagase et al., "Intercellular Adhesion Molecule-1 Mediates Acid Aspiration-Induced Lung Injury", Amer. J. Respir. Crit. Care Med., 154:504-510 (1996)
	Nakano, et al., "Adxanthromycins A and B, New Inhibitors of ICAM-1/LFA-1 Mediated Cell Adhesion Molecule from <i>Streptomyces</i> sp. NA-148", <i>J. Antibiotics.</i> , 53:12-18 (2000)
_	Nakao et al., "Monoclonal Antibodies Against ICAM-1 and LFA-1 Prolong Nerve Allograft Survival" Muscle & Nerve, 18:93-102 (1995)
	Oppenheimer-Marks et al., "Interleukin 15 is Produced by Endothelial Cells and Increases the Transendothelial Integration of T Cells In Vitro and in the SCID Mouse-Human Rheumatoid Arthritis Model In Vivo", <i>J. Clin. Invest.</i> , 101:1261-1272 (1998)
	Panés et al., "Role of Leukocyte-Endothelial Cell Adhesion in Radiation-Induced Microvascular Dysfunction in Rats", <i>Gastroenterology</i> , 108:1761-1769 (1995
	Pei et al., "Discovery of Potent Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-Ring) Structure-Activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides", <i>J. Med. Chem.</i> , 44:2913-2920 (2001)
	Prescott D., "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells", Methods in Cell Biology, 14:33-71 (1976)
	Qu et al., "The Role of the Divalent Cation in the Structure of the Domain I from the CD11a/CD18 Integrin", Structure, 4:931-942 (1996)
	Roche E., "Bioreversible Carriers in Drug Design, Theory and Application", <i>Pergamon Press</i> (face page and press info only) (1987)
	Sanfilippo P., "Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion", J. Med. Chem., 38:1057-1059 (1995)
	Schimmer et al., "Streptococcal Cell Wall-Induced Arthritis: Requirements for IL-4, IL-10, IFN-γ, and Monocyte Chemoattractant Protein-1", <i>J. Immunol.</i> , 160:1466-1471 (1998)
	Springer T., "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm", Cell, 76:301-314 (1994)
	Springer T., "Adhesion Receptors of the Immune System", Nature, 346:425-434 (1990)
	Stanley et al., "The I Domain of Integrin LFA-1 Interacts with ICAM-1 Domain 1 at Residue Glu-34 But Not Gln-73, <i>J. Biol. Chem.</i> , 273:3358-3362 (1998)
	Talento et al., "A Single Administration of LFA-1 Antibody Confers Prolonged Allograft Survival", Transplantation, 55:418-422 (1993)
	Tamiya et al., "Protective Effect of Monoclonal Antibodies Against LFA-1 and ICAM-1 on Myocardial Reperfusion Injury Following Global Ischemia in Rat Hearts", <i>Immunopharmacology</i> , 29:53-63 (1995)
	Tanaka et al., "Inhibition of Inflammatory Live Injury by a Monoclonal Antibody Against Lymphocyte Function-Associated Antigen-1", <i>J. Immunol.</i> , 151:5088-5095 (1993)

Atty. Docket No.	09095.0009-01000	Appln. No.	10/733,332
Applicant	WANG et al.		·
Filing Date	February 9, 2004	Group:	1614

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	von Andrian et al., "Two-Step Model of Leukocyte-Endothelial Cell Interaction in Inflammation: Distinct Roles for LECAM-1 and the Leukocyte β ₂ Integrins <i>In Vivo</i> ", <i>PNAS</i> , 88:7538-7542 (1991)			
	Wegner et al., "Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of Asthma", Science, 247:456-459 (1990)			
	Wegner et al., "Intercellular Adhesion Molecule-1 Contributes to Pulmonary Oxygen Toxicity in Mice: Role of Leukocytes Revised", <i>Lung</i> , 170:267-279 (1992)			
	Winn et al., "Discovery of Novel <i>p</i> -Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure-Activity Relationship of Substituents on the Benzene Ring of the Cinnamide", <i>J. Med. Chem.</i> , 44:4393-4403 (2001)			
	Zeng et al., "Inhibition of Transplant Rejection by Pretreatment of Xenogeneic Pancreatic Islet Cells with Anti-ICAM-1 Antibodies", <i>Transplantation</i> , 58:681-689 (1994)			
	Zhu et al., "Diels-Alder Reactions of Hexafluoro-2-butyne with 2-Heterosubstituted Furans: A Facile and General Synthesis of 1,4-Disubstituted 2,3-Di(trifluoromethyl) Benzenes", <i>Organic Letters</i> , 2:3345-3348 (2000)			
Examiner	Date Considered			
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO 144	9 Patent and Trademark Office - U.S. Department of Commerce			